Skip to main content
. 2023 Jan 18;120(4):e2202820120. doi: 10.1073/pnas.2202820120

Fig. 5.

Fig. 5.

Remdesivir and VRP-S vaccinations protected mice from 229E and NL63 infections. (A and B) For remdesivir treatment, Ad5-hAPN-transduced and Ad5-hACE2-transduced IFNAR−/− C57BL/6 mice were pretreated with remdesivir (50 mg/kg, bid s.c.) or equivalent vehicle at day -1 p.i., respectively. 229E and NL63 viral loads were determined by RT-qPCR. Viral loads are expressed as gene copies/g lung tissue [n = 3 (A) or n = 4 (B) mice per group per time point]. Data are representative of two independent experiments. (C and D) IFNAR−/− C57BL/6 mice were immunized with 2 × 105 infectious unit(IU) of 229E- VRP-S in the footpad in 50 μL PBS or immunized with 2 × 105 IU of NL63-VRP-S intranasally in 50 μL DMEM, respectively. Mice were transduced and infected with 1.5 × 105 TCID50 of 229E or 1.0 × 104 PFU of NL63 3 wk after VRP booster. 229E (C) or NL63 (D) viral loads in the lungs were measured at the indicated time points. Viral loads are expressed as gene copies/g lung tissue (n = 3 or 4 mice per group per time point). (*P ≤ 0.05, **P ≤ 0.005, ***P ≤ 0.0005, ****P ≤ 0.0001).